Brain Trust Bio
Brain Trust Bio is a next-generation biotechnology company focused on improving treatments for central nervous system (CNS) diseases by optimizing drug delivery methods and enhancing the performance of FDA-approved medicines. They aim to make existing therapies more effective and safer through innovative approaches such as continuous intrathecal drug delivery, with a focus on neurodegenerative diseases like ALS. The company is advancing clinical trials, including Phase I trials in Australia, and has a strong emphasis on scientific innovation, collaboration, and translational research.
Industries
Nr. of Employees
small (1-50)
Brain Trust Bio
3408 Clairmont Rd. #200 Brookhaven , GA 30319 United States
Products
Continuous intrathecal drug delivery method (development program)
A development program centered on a continuous intrathecal infusion approach intended to deliver small molecules directly to CSF and increase spinal cord exposure relative to oral dosing.
Continuous intrathecal drug delivery method (development program)
A development program centered on a continuous intrathecal infusion approach intended to deliver small molecules directly to CSF and increase spinal cord exposure relative to oral dosing.
Services
Preparation and conduct of non-clinical and regulatory activities to support investigational new drug study submissions and first‑in‑human trial initiation.
Development of intrathecal-compatible formulations for poorly soluble molecules and conduct of animal PK, distribution, and tolerability studies.
Execution of early-phase clinical trials including international site coordination, CSF sampling, and biomarker collection to support rapid progression to later phases.
Scientific advisory and clinical collaboration services drawing on expertise in neurosurgery, gene/cell delivery, stem cell biology, and neurodegenerative disease models.
Preparation and conduct of non-clinical and regulatory activities to support investigational new drug study submissions and first‑in‑human trial initiation.
Development of intrathecal-compatible formulations for poorly soluble molecules and conduct of animal PK, distribution, and tolerability studies.
Execution of early-phase clinical trials including international site coordination, CSF sampling, and biomarker collection to support rapid progression to later phases.
Scientific advisory and clinical collaboration services drawing on expertise in neurosurgery, gene/cell delivery, stem cell biology, and neurodegenerative disease models.
Expertise Areas
- Intrathecal drug delivery
- Formulation development for CNS delivery
- Preclinical pharmacology and toxicology
- Clinical trial management (Phase I / IND-enabled)
Key Technologies
- Intrathecal infusion delivery systems
- Cyclodextrin-based drug complexation for solubility
- Preclinical PK/PD animal models
- Implantable pump and catheter delivery